Revenue
2017
2019
2020
2021
2022
2023
2024
2025
Xenon Pharmaceuticals Inc. (XENE)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.5M | $0 | $0 | $9.4M | $18.4M | $32.2M | $6.8M | — | $311,000 | $1.8M | $15.6M | $28.4M | $27.4M | $14.3M |
| Research & development | $300.9M | $210.4M | $167.5M | $105.8M | $75.5M | $50.5M | $38.8M | $23.6M | $25.6M | $19.8M | $15.2M | $11.8M | $12.3M | $10.5M |
| Operating expenses | $380.6M | $279.3M | $214.1M | $138.6M | $97.4M | $63.5M | $49.6M | $38.0M | $32.9M | $26.6M | $24.9M | $17.3M | $17.6M | $17.5M |
| Operating income | −$373.1M | −$279.3M | −$214.1M | −$129.1M | −$79.0M | −$31.3M | −$42.8M | −$38.0M | −$32.6M | −$24.8M | −$9.4M | $11.1M | $9.7M | −$3.2M |
| EBITDAderived | −$370.5M | −$276.7M | −$212.0M | −$127.7M | −$78.1M | −$30.7M | −$42.4M | −$37.5M | −$31.9M | −$24.0M | −$8.3M | $11.8M | $10.4M | −$2.4M |
| Net income | −$345.9M | −$234.3M | −$182.4M | −$125.4M | −$78.9M | −$28.8M | −$41.6M | −$34.5M | −$30.7M | −$23.0M | −$15.8M | $13.0M | $12.0M | −$4.3M |
| Basic EPSper diluted share | -$4.36 | -$3.01 | -$2.73 | -$2.06 | -$1.77 | -$0.81 | -$1.54 | -$1.63 | -$1.71 | -$1.48 | -$1.10 | $4.11 | $2.87 | -$3.24 |
| Diluted EPSper diluted share | -$4.36 | -$3.01 | -$2.73 | -$2.06 | -$1.77 | -$0.81 | -$1.54 | -$1.63 | -$1.72 | -$1.48 | -$1.10 | $3.28 | $1.91 | -$3.24 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 5, 2026Form 4 · 10b5-1 | PATOU GARYDirector | SellCommon Shares | 1.3K | $53.14 | $70.3K | 24.9K |
| Jun 5, 2026Form 4 · 10b5-1 | Cannon GillianDirector | SellCommon Shares | 1.2K | $53.14 | $63.2K | 1.5K |
| Mar 13, 2026Form 4 · 10b5-1 | KENNEY CHRISTOPHER JOHNChief Medical Officer | SellCommon Shares | 1.4K | $55.23 | $77.9K | 7.1K |
| Mar 13, 2026Form 4 · 10b5-1 | DiFabio AndreaChief Legal Officer | SellCommon Shares | 1.3K | $55.23 | $74.1K | 7.3K |
| Mar 13, 2026Form 4 · 10b5-1 | MORTIMER IANPRESIDENT & CEO | SellCommon Shares | 7.3K | $55.23 | $403.6K | 19.9K |